Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Michael E Mertzman

Steven H Spergel

Ryan M Moslin

William John Pitts

Guanglin Luo

Carolyn Diane Dzierba

Jianliang Shi

Amy C Hart

John E Macor

Stephen T Wrobleski

David S Weinstein

John S Tokarski

Jie Chen

Junqing Guo

Yanlei Zhang

Sing-Yuen Sit

Chunjian Liu

Scott Hunter Watterson

Zili Xiao

Murugaiah Andappan Murugaiah Subbaiah

Alaric J Dyckman

Michael G Yang

Yong-Jin Wu

John L Gilmore

David Bertil Frennesson

Brian Lee Venables

Trevor C Sherwood

Shuqun Lin

Jason M Guernon

Matthew Reiser Patton

Xirui Hu

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Triazolopyridinyl compounds as kinase inhibitors

There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

Substituted heterocyclic compounds

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein. 

Aminoimidazopyridazines as kinase inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of formula I are useful for the treatment of inflammatory or autoimmune diseases. 

Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses

Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1; by acting on Tyk-2 to cause signal transduction inhibition.

Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN&#x3b1; responses

Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1; by acting on Tyk-2 to cause signal transduction inhibition. 

Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1;, by acting on Tyk-2 to cause signal transduction inhibition. 

Growing community of inventors

New Hope, PA, United States of America

Michael E Mertzman